Fighting sinus-derived Staphylococcus aureus biofilms in vitro with a bacteriophage-derived muralytic enzyme

International Forum of Allergy and Rhinology

Volumn 6, Issue 4, 2016, Pages 349-355

  Drilling, Amanda J ^a   Cooksley, Clare ^a   Chan, Chun ^a   Wormald, Peter John ^a   Vreugde, Sarah ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bacteriophage; Biofilms; Chronic rhinosinusitis; Lysins; Muralytic enzymes; Staphylococcus aureus

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEFALEXIN; CHIMERIC MURALYTIC ENZYME P128; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; FUSIDIC ACID; OXACILLIN; PENICILLIN DERIVATIVE; PSEUDOMONIC ACID; RIFAMPICIN; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN; HYBRID PROTEIN; LYSOSTAPHIN; N ACETYLMURAMOYLALANINE AMIDASE; P128 ANTISTAPHYLOCOCCAL CHIMERIC PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOFILM ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIOPHAGE; BACTERIUM ISOLATE; BIOFILM; CELL VIABILITY; CHRONIC RHINOSINUSITIS; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG EFFECT; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM BIOFILM ERADICATION CONCENTRATION; NONHUMAN; POST HOC ANALYSIS; PRIORITY JOURNAL; RESAZURIN ASSAY; SINUS DERIVED STAPHYLOCOCCUS AUREUS BIOFILM; DRUG EFFECTS; ENZYMOLOGY; MICROBIOLOGY; PARANASAL SINUS; PHYSIOLOGY; STAPHYLOCOCCUS AUREUS;

BACTERIOPHAGES; BIOFILMS; LYSOSTAPHIN; N-ACETYLMURAMOYL-L-ALANINE AMIDASE; PARANASAL SINUSES; RECOMBINANT FUSION PROTEINS; STAPHYLOCOCCUS AUREUS;

EID: 84951335015     PISSN: 20426976     EISSN: 20426984     Source Type: Journal    
DOI: 10.1002/alr.21680     Document Type: Article

References (41)

1. Ray GT, Suaya JA, Baxter R. Trends and characteristics of culture-confirmed Staphylococcus aureus infections in a large U.S. integrated health care organization. J Clin Microbiol. 2012;50:1950-1957.
2. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520-532.
3. Rodvold KA, McConeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis. 2014;58(Suppl 1):S20-S27.
4. Stryjewski ME, Corey GR. Methicillin-resistant Staphylococcus aureus: an evolving pathogen. Clin Infect Dis. 2014;58(Suppl 1):S10-S19.
5. Fraunholz M, Sinha B. Intracellular Staphylococcus aureus: live-in and let die. Front Cell Infect Microbiol. 2012; 2:43.
6. Fux CA, Costerton JW, Stewart PS, et al. Survival strategies of infectious biofilms. Trends Microbiol. 2005;13:34-40.
7. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-1322.
8. Foreman A, Wormald PJ. Different biofilms, different disease? A clinical outcomes study. Laryngoscope. 2010;120:1701-1706.
9. Bendouah Z, Barbeau J, Hamad WA, et al. Biofilm formation by Staphylococcus aureus and Pseudomonas aeruginosa is associated with an unfavorable evolution after surgery for chronic sinusitis and nasal polyposis. Otolaryngol Head Neck Surg. 2006;134:991-996.
10. Singhal D, Foreman A, Bardy JJ, et al. Staphylococcus aureus biofilms: nemesis of endoscopic sinus surgery. Laryngoscope. 2011;121:1578-1583.
11. Jervis-Bardy J, Foreman A, Field J, et al. Impaired mucosal healing and infection associated with Staphylococcus aureus after endoscopic sinus surgery. Am J Rhinol Allergy. 2009;23:549-552.
12. Schmelcher M, Donovan DM, Loessner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012;7:1147-1171.
13. Paul VD, Rajagopalan SS, Sundarrajan S, et al. A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein. BMC Microbiol. 2011;11:226.
14. George SE, Chikkamadaiah R, Durgaiah M, et al. Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128. BMC Res Notes. 2012;5:280.
15. Vipra AA, Desai SN, Roy P, et al. Antistaphylococcal activity of bacteriophage derived chimeric protein P128. BMC Microbiol. 2012;12:41.
16. Junjappa RP, Desai SN, Roy P, et al. Efficacy of anti-staphylococcal protein P128 for the treatment of canine pyoderma: potential applications. Vet Res Commun. 2013;37:217-228.
17. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard. 11th edition. M02-A11, Vol. 32, No. 1. Replaces M02-A10, Vol. 29, No. 1. Wayne, PA: CLSI; January, 2012. http://antimicrobianos.com.ar/ATB/wp-content/uploads/2012/11/01-CLSI-M02-A11-2012.pdf. Accessed November 23, 2015.
18. O'Brien FG, Udo EE, Grubb WB. Contour-clamped homogeneous electric field electrophoresis of Staphylococcus aureus. Nat Protoc. 2006;1:3028-3033.
19. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233-2239.
20. Jardeleza C, Foreman A, Baker L, et al. The effects of nitric oxide on Staphylococcus aureus biofilm growth and its implications in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2011;1:438-444.
21. Drilling A, Morales S, Jardeleza C, et al. Bacteriophage reduces biofilm of Staphylococcus aureus ex vivo isolates from chronic rhinosinusitis patients. Am J Rhinol Allergy. 2014;28:3-11.
22. Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1:111-114.
23. Keen EC. Phage therapy: concept to cure. Front Microbiol. 2012;3:238.
24. Meng X, Shi Y, Ji W, et al. Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen Streptococcus suis. Appl Environ Microbiol. 2011;77:8272-8279.
25. Domenech M, García E, Moscoso M. In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. Antimicrob Agents Chemother. 2011;55:4144-4148.
26. Díez-Martínez R, De Paz HD, García-Fernández E, et al. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J Antimicrob Chemother. 2015;70:1763-1773.
27. Oliveira H, Thiagarajan V, Walmagh M, et al. A thermostable Salmonella phage endolysin, Lys68, with broad bactericidal properties against gram-negative pathogens in presence of weak acids. PLoS One. 2014;9:e108376.
28. Gutiérrez D, Ruas-Madiedo P, Martínez B, et al. Effective removal of Staphylococcal biofilms by the endolysin LysH5. PLoS One. 2014;9:e107307.
29. Sass P, Bierbaum G. Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol. 2007;73:347-352.
30. Son J-S, Lee S-J, Jun S, et al. Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Appl Microbiol Biotechnol. 2010;86:1439-1449.
31. Singh PK, Donovan DM, Kumar A. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob Agents Chemother. 2014;58:4621-4629.
32. Jun SY, Jung GM, Yoon SJ, et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother. 2014;58:2084-2088.
33. Rujanavej V, Soudry E, Banaei N, et al. Trends in incidence and susceptibility among methicillin-resistant Staphylococcus aureus isolated from intranasal cultures associated with rhinosinusitis. Am J Rhinol Allergy. 2013;27:134-137.
34. Datta R, Shah A, Huang SS, et al. High nasal burden of methicillin-resistant Staphylococcus aureus increases risk of invasive disease. J Clin Microbiol. 2014;52:312-314.
35. von Eiff C, Becker K, Machka K, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001;344:11-16.
36. Jun SY, Jung GM, Yoon SJ, et al. Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents. 2013;41:156-161.
37. Lina G, Boutite F, Tristan A, et al. Bacterial competition for human nasal cavity colonization: role of Staphylococcal agr alleles. Appl Environ Microbiol. 2003;69:18-23.
38. Uehara Y, Nakama H, Agematsu K, et al. Bacterial interference among nasal inhabitants: eradication of Staphylococcus aureus from nasal cavities by artificial implantation of Corynebacterium sp. J Hosp Infect. 2000;44:127-133.
39. Abreu NA, Nagalingam NA, Song Y, et al. Sinus microbiome diversity depletion and Corynebacterium tuberculostearicum enrichment mediates rhinosinusitis. Sci Transl Med. 2012;4:151ra124.
40. Boase S, Foreman A, Cleland E, et al. The microbiome of chronic rhinosinusitis: culture, molecular diagnostics and biofilm detection. BMC Infect Dis. 2013;13:210.
41. Feazel LM, Robertson CE, Ramakrishnan VR, et al. Microbiome complexity and Staphylococcus aureus in chronic rhinosinusitis. Laryngoscope. 2012;122:467-472.